BioMarin Pharmaceutical Inc.

Goldman Sachs remains bullish on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) despite the company withdrawing its EU application for Kyndrisa in Duchenne muscular dystrophy (DMD). The move follows the May 23-26 CHMP meeting which indicated a negative opinion was forthcoming. Saying that the...